| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 78,022 | 43,134 |
| Proceeds from the exercise of stock options | 246 | 161 |
| Proceeds from the purchase of common stock under espp | 434 | 434 |
| Net cash provided by financing activities | 680 | 595 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -23,502 | -27,427 |
| Cash and cash equivalents at beginning of period | 74,241 | - |
| Cash and cash equivalents at end of period | 50,739 | - |
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)